Ilko Pharmaceuticals is a family-owned Turkish generics and biosimilars company. General Manager Hatice Öncel explains the company’s investment in biosimilars in collaboration with South Korea’s Genexine and how recent success in consumer health has allowed them to overperform the local market with 27 percent growth in 2020. In addition, she discusses the upcoming biosimilars legislation in Turkey, the complications of succeeding in the European market due to low margins, and the opportunities in the CIS and MEA regions.
We are close to having the technological capacity to develop all types of biosimilar products, even some novel ones
